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Dengue virus has four serotypes that cause a public health problem in Indonesia. Currently, there is no
preventative vaccine for this disease, but some model vaccines are in development. The envelop (E) pro-
tein genes from three isolates of dengue virus (DENV-1, -3 and -4) were isolated, cloned into Escherichia
coli and then sub-cloned into a baculovirus vector before co-transfection into Sf9 cells. Recombinant E
genes were inserted between the Smal and Sacl sites of the plasmid, adjacent to the baculoviral structural
gene, polyhedrin. The sequence of recombinant E gene was relatively stable with 97–98% homology,
although there were amino acid substitutions in some regions. The recombinant protein was more
antigenic when exposed to polyclonal sera from infected humans than sera from immunized mice, but
its binding to monoclonal antibodies IgG1a and IgG2b was stronger than other isotopes, including IgM,
IgG and Ig1b. Recombinant E protein induced cellular immune responses in immunized mice, as demon-
strated by lymphocyte secretion of IL-3. This study indicates that recombinant E protein expressed in a
baculovirus system can induce humoral and cellular immune responses.
 2013 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Dengue virus is negative-sense, single-stranded RNA virus of
the Flavivirus family; it has four serotypes that are endemic across
Indonesia [12,15] and other tropical countries. The virus causes
mostly pediatric morbidity and mortality [5]. The two types of den-
gue virus protein are structural and non-structural; their functions
are genome replication (polymerase) and induction of antibodies.
Structural proteins include the capsid (C), premembrane (prM),
matrix (M) and envelop (E) proteins. E protein is important for
attachment to cell membranes during infection, and it has many
epitopes that react with neutralizing antibodies (Rey et al., 1995).
Envelope protein is a glycoprotein, which has been studied for its
antigenicity and immunogenicity [2,6] and especially explored anepitope type [10]. The severity of dengue virus disease was corre-
lated with serotype. Serotypes 2 and 3 are more virulent than
serotypes 1 and 4 [15], although antibody dependent enhancement
has an effect [11]. Thus, vaccines would be effective in preventing
dengue virus infections.
Potential dengue virus vaccines have been developed, but they
may not protect against all serotypes. Recombinant protein
vaccines with many epitopes have been produced for yellow fever
virus and baculovirus (lobigs et al., 1987; [17], but it is not clear
which antigen determines the induction of neutralizing antibod-
ies. The baculovirus expression system has been used extensively
for the expression of recombinant proteins [7] because it is a
large, enveloped virus with double-stranded, circular DNA gen-
ome [4]. In this paper, we used a baculovirus system to express
a multivalent, recombinant E protein for vaccine subunit develop-
ment. The baculovirus insect cell expression system has been
extensively developed. The most commonly used insect host cells
include the Sf9 and sf21AE cell lines, originally derived from
Spodoptera frugiperda pupal ovarian tissue [7]. In our studies,
Sf9 cells were used.
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Virus and clinical specimens
The DENV-1, -3 and -4 strains were isolated from the sera of 62
human patients. Serum samples were collected by Dr. Soegijanto of
the Child Health Department, Dr. Soetomo Teaching Hospital/
School of Medicine, Airlangga University, from 2000 to 2008.
Dengue virus isolates were selected by their biological properties,
including cytopathic effect (CPE) and plaque-forming unit titers
on infected Vero cells. Vero cells were kindly provided by Dr.
Morita at Nagasaki University. DENV-1, -3 and -4 strains were
isolated in 2008, 2004 and 2003, respectively, at the Dengue
Hemorrhagic Fever laboratory, Institute of Tropical Disease,
Airlangga University, Surabaya, Indonesia, and were identiﬁed by
multiplex RT-PCR as described by Lanciotti et al. [8].
RNA extraction, RT-PCR ampliﬁcation, cloning and transfection
RNA was extracted from the supernatants of Vero cells infected
with DEN-1, -3, or -4 and reverse transcribed to cDNA using ran-
dom hexamer primers. cDNA was ampliﬁed using PCR conditions
modiﬁed from Bielefeldt-Ohmann et al. [1] and Dos Santos et al.
(2004). The following primers were used: forward Den1/Env/50-G
GGGGCTTCAACATCCCAAG-30, reverse Den1/Env/50-GTGCTCC ACG
GGCAGTTGTC-30, forward Den3/Env/50-AGGGGCTACAAC AGAA AC
AC-30, reverse Den3/Env/50-TTGCACCTCTGGCAGTGGCC-30, forward
Den4/Env/50-AGGAGCAGACACATCAGAAG-30, reverse Den4/Env/50-
TTGCACCTCTGTATGTGGAC-30. PCR products were digested with
the restriction endonuclease EcoR1, which cleaves at the joining
site of the three E proteins, to minimize disruptions to protein sec-
ondary structure. The E protein genes were cloned individually into
plasmid pGem and shuttle vectors (Promega) and subsequently li-
gated at the EcoR1 sites. The sequences were subcloned into the
baculovirus transfer vector pVL (Stratagene). For cloning and
transfer into the baculovirus transfer vectors, Smal and Sac1 were
used at the 50 and 30 ends, respectively, according to the modiﬁed
method of Deuble et al. [3] and Kost and Condreay [7]. The
recombinant virus was transfected according to the method of
Bielefeldt-Ohmann et al. [1]. To ensure the molecular properties
of recombinant E protein, the truncated protein E PCR product
was sequenced using a method modiﬁed from Ong et al. [12],
and amino acid analysis was performed using ClustalW Mega 5
software.
Production of recombinant E protein
Conﬂuent Sf9 cell monolayers in 75-cm2 tissue culture ﬂasks
were inoculated with the recombinant baculoviruses at an MOI
of 1 in 3 ml medium. After 1 h, 7 ml serum-free medium was
added. The conditioned medium was collected after 72 h, and the
proteins were precipitated with 9% ﬁnal concentration sterile poly-
ethylene glycol 6000 (PEG, BDH) and overnight incubation with
stirring at 4 C. The precipitates were pelleted by centrifugation
at 14,000g for 5 h and resuspended in sterile TNE buffer. The pro-
tein was used directly for analysis using a method modiﬁed from
Bielefeldt-Ohmann et al. [1].
SDS–PAGE and western blotting
The recombinant dengue virus envelope proteins were sepa-
rated using non-reducing 12% SDS–PAGE. The proteins were trans-
ferred onto nitrocellulose membranes by electroblotting in a
methanol, glycine and Tris-buffer, and membranes were blocked
with 1% bovine serum albumin (BSA) for 1 h [14]. The membraneswere incubated with dengue virus-speciﬁc primary monoclonal
antibody (mAb). After washing with Tris-buffered saline contain-
ing 0.1% Tween 20 and 1% BSA, primary polyclonal antibody was
added. Following the washes, alkaline phosphatase-conjugated
rabbit anti-mouse antibody (Dako) was added. Finally, nitrocellu-
lose membranes were stained with Fast Red.Immunotyping – ELISA
Microplates (96-well, Nunc) were coated with puriﬁed recom-
binant protein overnight at 4 C, washed with PBS containing
Tween 20 (PBST) and blocked for 1 h at room temperature with
1% BSA. After three washes with PBST, the primary mAb goat
anti-mouse IgM, IgG, Ig1a, Ig1b and Ig2b (Dako) were diluted
appropriately in PBS and incubated on the plates for 1 h at 37 C.
After three washes with PBST, horseradish peroxidase-conjugated
anti-mouse immunoglobulin (Dako) was diluted in PBS and added
to the wells. Following incubation for 45 min at 37 C, the plates
were washed three times with PBST, and ortho-phenylenediamine
(OPD) substrate (Sigma) was added. The plates were incubated
10 min in the dark. After the addition of 1 M HCl, the plate was
read on an ELISA reader (Bio-Rad) with the 450-nm wavelength.
This method was modiﬁed from Bielefeldt-Ohmann et al. [1] and
Rantam [14].Immunization of mice and spot-ELISA
Three groups of 15 BALB/c mice (male, Veterinary Farma, Sura-
baya, Indonesia) were immunized by the intraperitoneal route
with 15 lg of puriﬁed recombinant E protein mixed with Monta-
ned 70 adjuvant (Seppic, Institute Pasteur). All mice were sacriﬁced
at 14 days post-immunization, and spleen cells were isolated as
described by Bielefeldt-Ohmann et al. [1] to analyze the secreted
cellular immune response by ELISpot as described by Mabtech.
All animal experiments were conducted with institutional ethics
approval in accordance with the Faculty of Veterinary Medicine,
Airlangga University, Surabaya, Indonesia.Results
Virus culture and identiﬁcation
Dengue viruses caused cytopathogenic effect (CPE) in 60–80% of
Vero cells after passage 3–4, indicating that the virus was growing
in these cells. Viruses were harvested, and RNA was extracted for
serotype identiﬁcation. The virus titers were determined by indi-
rect ELISA (data not shown). While all dengue virus serotypes in-
duced CPE in cell culture, DENV-4 replicated less rapidly than
DENV-1 and DENV-3, as shown in Fig. 1. RT-PCR was used to iden-
tify dengue virus isolate serotypes.
In Fig. 2b, cDNA was ampliﬁed from the selected serotypes. The
E protein genes of DENV-1, -3 and -4 were cloned individually and
subsequently fused in a single plasmid, as illustrated in Fig. 3. To
construct the recombinant envelope protein gene, a DNA fragment
of 1744 nucleotides was cloned. The dengue virus E protein gene in
this construct was placed under the transcriptional control of the
baculovirus polyhedrin promoter. Additionally, the dengue virus
RNA transcripts contained an authentic initiation codon and pro-
duced recombinant E proteins (Fig. 3). The recombinant DNA and
baculovirus genomic DNA were co-transfected into Sf9 cells,
resulting in homologous recombination, as indicated by western
blotting and plaques in Sf9 cells (Fig. 4a, b and Fig. 5a).
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Fig. 1. Dengue virus-infected Vero cells. (N) Normal Vero cell. (A) Vero cells infected with DENV-4 at six days after inoculation. (B) Vero cells infected with DENV-1. (C) Vero
cells infected with DENV-3. The CPE observed for DENV-1 and DENV-3 were relatively similar, although the virus virulence in vitro was very different. Arrows indicate
cytopathic effect.
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Fig. 2. (A) Identiﬁcation of dengue virus serotypes in supernatants of infected Vero cells using multiplex RT-PCR. Lane D1: DENV-1, Lane D3: DENV-3, Lane D4: DENV-4, Lane
N: negative control and Lane M: marker. (B) PCR was used to amplify the dengue envelope genes of DENV-1, -3 and -4 (ED-1, -3 and -4) from infected Vero cells. Serotype-
speciﬁc primers resulted in PCR products of approximately 582 bp. Lane p; the positive control DENV-2.
F666 F601
R1229
F668
R1222R1228
A
m
pl
ifi
ca
tio
nED1 ED3 ED45’ 3’
Cloning & Fusion gene
pVL , 9,8 kb
SmalSac 1
pVL DEΔHIS
11,00 kb
PrPH
PrPH
EΔH6
Smal - Sac1 
Frag. Prot E. AUG-nt 892 
SSEΔ nt 2092 Stop Sac1
Autographa Californica Nuclear Polyhidrosis Virus (AcNPV)
Infected  sf9 cells (Prototype of  recombinant E  protein  multivalent)
Insertion
Fig. 3. Construction of recombinant envelope (E) protein. DENV-1, -3 and -4 E genes
were inserted into the baculovirus system using an intermediate vector. Vector pVL
contains the polyhedrin structural gene. A fragment of the viral structural protein
open reading frame (nucleotides 892–2092) was ligated into the SmaI site of pVL.
The recombinant cDNA fragment containing the insert in the sense orientation was
isolated for the construction of recombinant baculovirus, which was transfected
into AcNPV cells. Sf9 cells were infected with the resulting baculovirus.
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Recombinant envelope protein genes from DENV-1, -3 and -4
(ED1, ED3, ED4) were cloned into a baculovirus vector, which
was transfected into Sf9 cells. Some virus plaques were formed
in these cells (Fig. 4a). DNA puriﬁed from plaques in Sf9 cell cul-tures was used to evaluate the stability of recombinant E protein
genes. The results from alignment analyses in the ClustalWMEGA5
software are shown in Fig. 4b and Table 1. Nucleotides were
97–98% homologous and stable, although there were some amino
acid substitutions (Table 2).
Amino acid substitutions are shown in Table 2. There were no
dominant changes, but in the region of recombinant E protein
ED1, there were only serine (S) and cysteine (C) to arginine changes
with E value scores of 2e-132.
Recombinant dengue virus E proteins have some nucleotide
changes. Some regions of ED1 and ED3 have the highest and lowest
scores, respectively, with 97–98% similarity to the original se-
quence and 5,3% variable sites (Table 1).
There were no amino acid variants except serine (S) to arginine
(R), cysteine (C) to arginine, lysine (K) to glutamate (E), histidine
(H) to tyrosine (Y), phenylalanine (F) to leucine (L), valine (V) to
alanine (A) and glutamate to asparagine (N) changes (Table 2).Antigenicity and reactivity of recombinant E protein
Recombinant E proteins were puriﬁed from baculovirus-
infected Sf9 cells, digested with a naphthol 40 solution, separated
by SDS–PAGE and transferred onto nitrocellulose membranes
using an electroblotter (Goettingen) (Fig. 5a, b).
Puriﬁed recombinant E proteins were isolated using Talon
(Invitrogen) and mixed with the adjuvant surfactant monteneid-
SEPPIC (Institute Pasteur, France); each mouse was immunized
with 15 lg of the mixture. The reaction of recombinant E protein
with monoclonal antibody (mAb) was analyzed using indirect ELI-
SA (Fig. 6). Recombinant E protein showed the highest reactivity to
IgG1a and IgG2b.
ELISpot assays were used to analyze the immunogenic function
of recombinant E protein (Fig. 7a). Interleukin-3 in immunized
mice (group 1) was relatively high, and spot counts were similar
in a replicate experiment (group 2). These results indicate that re-
combinant E proteins induced a robust cellular immune response.
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Fig. 4. RT-PCR assay of recombinant E protein using a b-actin control. (A) Agrophaga cells infected with recombinant baculovirus. The arrowhead indicates an infected cell. (B)
M: marker, Lane 1: cells infected with baculovirus, Lane 2: non-infected cells, Lanes 3–5: cells infected with recombinant baculovirus.
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Fig. 5. Antigenic reactivity of recombinant E proteins. (A) Western blotting: Recombinant E proteins were separated by 12% SDS–PAGE, transferred onto nitrocellulose
membranes and incubated with dengue virus-speciﬁc antibody after blocking with 1% BSA. Lane M: protein marker, Lane 1: recombinant E protein was reacted with MAb
IgG1a. Lanes 2, 5, 6: Visualization of recombinant E protein reacted with sera from DHF patients, which was collected by ITD from Dr. Soetomo Teaching Hospital-UA. Lane 4:
recombinant E protein was reacted with MAb IgG2b. N: recombinant E protein was reacted with normal human sera and stained with Fast Red. (B) Western blot analysis
showed weak reactivity. Lane 1: Recombinant E protein was incubated with mAb IgG1a. Lanes 2–6: Recombinant E protein was reacted with sera from immunized mice. Lane
N: normal sera from unimmunized mice. Arrowheads indicate a molecular mass of 52 kDa, and the molecular mass markers at 32 and 49 kDa are indicated. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 1
Nucleotide homology between recombinant E genes and the original DENV-1, -3, and
-4 E gene sequences.
Description Max score Total score Query cover E Value Identity
ED1 359 359 98% 2e-132 98%
ED3 354 354 100% 3e-130 97%
ED4 355 355 99% 7e-131 98%
Table 2
Amino acid substitutions in the recombinant E protein regions ED-1, -3, and -4.
Comparing Amino acid changing
Original sequence S C K H F V E
Recombinant sequence ED1 R R
Recombinant sequence ED3 E Y L
Recombinant sequence ED4 A N
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Fig. 6. Analysis of recombinant E protein antigenicity. Indirect ELISA was used to
conﬁrm that recombinant E protein induced an immune response. Recombinant E
proteins were reacted with various isotypes of mAb (IgM, IgG, IgG1a, IgG2a, IgG2b).
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cell had a different production of IL-3 (Fig. 7b).Discussion
Dengue viruses have different levels of virulence. These viruses
were isolated via blind passaging or 3–4 subcultures in Vero cells.
Replicating virus was identiﬁed by the induction of cytopathic
effect (CPE) (Fig. 1), although not all serotypes caused CPE in cell
cultures. To identify virus serotypes, multiplex RT-PCR was used
as in Lanciotti et al. [8], and different products were observed in
each serotype (Fig. 2a). The expression of dengue viral recombinant
E protein of virus infected cells contained antigen have showed
some plaque forming unit in Sf9 as in Fig. 4a. This result indicates
that viral proteins were expressed from baculovirus vectors, regen-
erating viruses in Sf9 cells.
Protein expression was analyzed by western blotting. Proteins
were separated by SDS–PAGE, transferred to nitrocellulose mem-
branes and strafed 3 mm. The results show that the reactivity of re-
combinant E protein with monoclonal IgG1a and IgG1a antibody is
relatively weak compared with the reactivity of sera from DHF pa-
tients. Thus, the protein recognized more polyclonal than mAbs,
although the reactivity of protein and antibody was signiﬁcantly
different (Fig. 5a) because the immune response to dengue virus
protein depends on the individual infected dengue virus [13].
However, polyclonal antibodies from the sera of humans infected
with dengue virus can possibly react to many types of non-speciﬁc
dengue virus epitopes. The antigenicity of recombinant E protein in
polyvalent immunized mice sera was weaker than in sera from hu-
mans infected with dengue virus (Fig. 5b). Because the immuniza-
tion of mice consisted of a single dose, it is possible that
antigenicity would be higher with 2–3 booster immunizations
[1]. In this case, recombinant E protein induced strong responses
in BALB/c mice.
To analyze cellular response immunes, lymphocytes from
immunized mice were cultured in vitro with recombinant E pro-
tein. ELISpot analysis showed that IL-3 was secreted in vitro by
all lymphocytes. In this case, the original secretion of IL-3 was very
difﬁcult to prove, and currently no other data supports this ﬁnding.
Secreted IL-3 was not detected in normal lymphocytes from the
Fig. 7. Mice lymphocytes secreting IL-3 were analyzed by ELISpot after four days of in vitro culture. (A) IL-3 spots; n = 5 mice. Control: immunized using the adjuvant Seppic,
group 1: lymphocytes frommice immunized with recombinant E proteins, group 2: lymphocytes frommice immunized with inactive dengue virus (DENV-1, -3 and -4) at 107
TCID50. (B) Representative ELISpot of IL-3 secreted from mice immunized mice with recombinant E protein. The white arrowhead indicates IL-3 spots.
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signiﬁcantly different from the control group. The level of secreted
IL-3 may be correlated with the recognition of an epitope of the re-
combinant protein. This event occurs before stimulated macro-
phages release IFN-c, which initiates signaling in the cellular
immune response [9,1].
Lymphocyte susceptibility depends on age, strain, animal and
route of immunization [16]. The type of adjuvant and recombinant
E protein structure, but not amino acid changes, may contribute
less to immunogenicity. In contrast, changing the amino acids ser-
ine, alanine, histidine and asparagine in recombinant E proteins
could lead to the induction of a stronger immune response or en-
hanced antibodies. In these cases, amino acid changes can inﬂu-
ence the recombinant E protein structure. Because this system
produces relatively stable recombinant E protein, immunogenic
proteins can be developed via this method for use in multivalent
vaccines or diagnostic tests.
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